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Background: Non-small cell lung cancer (NSCLC) with brain metastasis (BM) harboring an epidermal growth factor
receptor (EGFR) mutation shows good response to tyrosine kinase inhibitors (TKIs). This study is to assess the
appropriate timing of brain radiotherapy (RT) for asymptomatic BM in EGFR mutant NSCLC patients.
Methods: There were 628 patients diagnosed with EGFR mutant NSCLC between October 2005 and December
2011. Treatment outcomes had been retrospectively evaluated in 96 patients with asymptomatic BM without prior
TKI treatment. 39 patients received first-line brain RT, 23 patients received delayed brain RT, and 34 patients did not
receive brain RT.
Results: With a median follow-up of 26 months, the 2-year OS was 40.6 %. Univariate analyses revealed that ECOG
performance status (p = 0.006), other distant metastases (p = 0.002) and first line systemic treatment (p = 0.032) were
significantly associated with overall survival (OS). Multivariate analyses revealed that other sites of distant metastases
(p = 0.030) were prognostic factor. The timing of brain RT was not significantly related to OS (p = 0.246). The 2-year BM
progression-free survival (PFS) was 26.9 %. Brain RT as first-line therapy failed to demonstrate a significant association
with BM PFS (p = 0.643).
Conclusions: First-line brain RT failed to improve long-term survival in TKI-naïve EGFR mutant NSCLC patients with
asymptomatic BM. Prospective studies are needed to validate these clinical findings.
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Brain metastasis (BM) is a common complication of lung
cancer and is associated with poor treatment outcomes.
BM is observed in approximately 25–30 % of non-small
cell lung cancer (NSCLC) patients [1]. The median sur-
vival is approximately 4–11 weeks in untreated patients
but can be improved by whole-brain radiation therapy
(WBRT) to 3–6 months [2]. However, NSCLC has been
regarded as a relatively radio-resistant malignancy, and
30 Gy WBRT may be insufficient to destroy the lesions;
recent studies have suggested that the median response
rate to WBRT remains approximately 25–30 % [3]. The
role of chemotherapy in the treatment of brain metastasis
remains controversial.
Advances in the understanding of the molecular biology
of tumors have led to the development of targeted agents
with promising results in the treatment of NSCLC. Epider-
mal growth factor receptor (EGFR) mutations are associ-
ated with a significant sensitivity to EGFR tyrosine kinase
inhibitors (TKI), which can significantly improve treatment
outcome [4]. Recently, the efficacy of epidermal growth
factor receptor tyrosine kinase inhibitors (EGFR-TKIs) for
NSCLC patients with BM has been reported [5, 6]. More-
over, several reports demonstrate that NSCLC patients
with mutant EGFR and BM could also achieve favorable
outcomes when treated with EGFR-TKIs as single-agent
chemotherapy. Several studies have reported that TKI
treatment results in high response rates (70–89 %) and in-
creased overall survival (OS) and progression-free survival
(PFS) (12.9–19.8 months and 6.6–23.3 months, respect-
ively) in selected populations of EGFR-mutated NSCLC
patients with BM [7–9].
Several studies have suggested that patients with BM har-
boring EGFR mutations may have higher response rates to
WBRT than those with wild-type tumors [10–13].
However, unlike the EGFR-mutant primary lung tumor,
11–44 % of brain metastases exhibit resistance to TKI treat-
ment [7, 8]. In addition, Omuro et al. [14] reported a high
incidence of central nervous system (CNS) metastases dur-
ing the course of a standard treatment of gefitinib, an EGFR
inhibitor, despite good control of other disease sites. These
results suggest that local therapy may still be important for
the treatment of BM in patients with EGFR mutations.
However, for EGFR-mutant NSCLC patients with
asymptomatic brain metastasis who do not require ur-
gent symptom relief, the proper treatment schedule is
not well established. Therefore, we sought to gain insight
from the retrospective analysis of patients treated with
different combinations of irradiation/TKI therapies.
Methods
Acquisition of clinical data
A total of 628 patients were diagnosed with adenocar-
cinoma of the lung harboring EGFR mutations betweenOctober 2005 and December 2011 at the Sun Yat-Sen
University Cancer Center. Treatment outcomes had
been retrospectively evaluated in 96 patients with
asymptomatic BM without prior TKI treatment. Before
receiving treatment, each patient underwent a physical
examination, laboratory tests and electrocardiograms as
well as a medical history evaluation, including documen-
tation of concomitant medications, performance status,
and smoking history. Patient data included chest and
upper abdomen computed tomography (CT) scans or
positron emission tomography (PET) scans, bone scans,
and magnetic resonance imaging (MRI) of the brain.
Tumor stage was classified using the tumor/node/metas-
tasis (TNM) system proposed by the American Joint
Committee on Cancer (8th edition). T and N stage were
determined on the basis of the findings of CT with or
without additional fiberoptic bronchoscopy. Mediastinal
lymph nodes ≥1 cm on transaxial CT images or SUV ≥
2.5 on PET scans were considered positive. All patients
were required to meet the following inclusion criteria: 1)
pathologically confirmed NSCLC harboring an activating
EGFR mutation; 2) documented measurable brain me-
tastases (AJCC stage IV disease) at first diagnosis; and 3)
Eastern Cooperative Oncology Group (ECOG) perform-
ance status ≤3. Patients with severe comorbid conditions
and other active malignancies were excluded from the
analysis.
EGFR Genotyping
All patients provided written informed consent for the
comprehensive use of molecular analysis. Genomic DNA
was isolated from paraffin-embedded tissues, which were
obtained by transbronchial lung biopsy or from cytologic
materials, such as bronchial lavage fluid and pleural effu-
sions. Methanol-fixed cytologic specimens were used for
DNA extraction for patients for whom only cytologic
sample were available at initial diagnosis. Epidermal
growth factor receptor mutation analysis of all of the pa-
tients was performed by direct sequencing or the ARMS
method at the Department of Molecular Diagnosis [15].
Follow-up and treatment response assessment
The beginning of the follow-up period was defined as
the initial date of local or systemic treatment. Patients
underwent chest, abdomen, and pelvic CT and brain
MRI every three months until disease progression. Bone
scans were administered when patients were suspected
of having bone metastasis. Positron emission tomog-
raphy scans were administered when systemic progres-
sion was expected. The rates and times of treatment
response, overall survival, local relapse and distant me-
tastases were recorded.
Systemic disease at the time of BM diagnosis was con-
sidered active if a chest, abdomen and pelvic CT, PET,
Table 1 Clinical and molecular characteristics of patients (n = 96)
Charateristics Patients (n = 96) No.(%)
Sex
Male 34 (35.4 %)
Female 62 (64.6 %)
Age(year), median(range) 54 (26–79)
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BM diagnosis revealed new sites of extra-cranial metas-
tases or progression at previously known sites of disease.
The time to brain progression was measured from the
initial date of local or systemic treatment until the date
of radiological progression or worsening neurological
symptoms at the time of last follow-up.aECOG performance status
0–1 69 (71.9 %)
2–3 27 (28.1 %)
No. of brain lesions
1–4 32 (33.3 %)
>4 64 (66.7 %)
Max size of brain lesions
<1 cm 75 (78.1 %)
>1 cm 21 (21.9 %)
Location of brain lesions
Brain stem mets 13 (13.5 %)
Non-brain stem mets 83 (86.5 %)
Other sites of metastatic disease
Yes 61 (63.5 %)Statistical analysis
The study endpoint was OS. Overall survival was calcu-
lated as the time from the initial date of local or systemic
treatment to the date of death from any cause or to the
last visit before March 31, 2014, censored at the date of
last follow up. Each variable was assessed first in univariate
analysis, and the variables with a P value <0.10 were evalu-
ated by multivariate analysis. Survival curves were plotted
using the Kaplan-Meier method. We fit the proportional
hazards model using Cox regression. After testing for vari-
able interactions, a forward stepwise elimination pro-
cedure was used to determine the best-fitting model.
P values <0.05 were regarded as statistically significant
in multivariate analysis. All statistical analyses were
performed using SPSS 19.0 software (IBM).No 35 (36.5 %)
bEGFR mutation
Exon 19 45 (46.9 %)
Exon 21 51 (53.1 %)
First line systemic treatment
Chemotherapy 61 (63.5 %)
cTKI 35 (36.5 %)
Time of Brain radiotherapyEthics statement
Participants’ information collection was guaranteed by
Ethics Committee of Sun Yat-sen University Cancer Cen-
ter. Written informed consent was not obtained, instead,
all clinical records was anonymized and de-identified prior
to analysis. All authors have read and approved the
manuscript.First line 39 (40.6 %)
Delayed 23 (24.0 %)
No dRT 34 (35.4 %)
aEastern Cooperative Oncology Group




The patient characteristics are detailed in Table 1. The
study included 96 patients, with 62 females and 34
males. There were 50 patients with BM at the initial
diagnosis of NSCLC (stage IV), the other 46 patients de-
veloped BM after first-line treatment. None of the pa-
tients received TKI therapy before the diagnosis of BM.
None of the patients experienced any symptoms related
to the metastatic brain tumors. After diagnosis and gen-
eral evaluation, all 96 patients received either chemo-
therapy or a TKI as systemic treatment. The regimens
included cisplatin or carboplatin combined with pacli-
taxel or pemetrexed. All 61 patients exhibited disease
progression and were administered a TKI as second-line
systemic treatment after the diagnosis of BM. The 35 pa-
tients who received TKI as first-line therapy after the
diagnosis of BM were treated with 250 mg of oral gefi-
tinib or 150 mg of erlotinib once daily until disease pro-
gression or unacceptable toxicity.Survival and prognostic factors
With a median follow-up of 26 months (range, 11–56
months), the 2-year OS was 40.6 %, and the estimated
OS time was 21.0 months (Fig. 1). Eastern Cooperative
Oncology Group performance status (p = 0.006), other
distant metastases (p = 0.002) and first line systemic
treatment (p = 0.032) were significantly associated with
OS (Table 2). The clinical factors that were statistically
significant (p < 0.10) in a univariate analysis were ana-
lyzed further in a multivariate analysis with a stepwise
selection of variables. Only other sites of distant metas-
tases (p = 0.030) were selected by a stepwise selection of
factors in the final models (Table 3).
Fig. 1 Overall survival since the initiation of treatment (n = 96): The
2-year OS was 40.6 %, with a median follow-up of 26 months (range,
11–56 months), and the estimated overall survival time was 21.0 months
Table 2 Univariate analysis of prognostic factors of overall
survival (n = 96)
Variable HR, 95 % CI p value
Sex 0.81 (0.43–1.55) 0.534
(male vs. female)
Age 0.74 (0.39–1.41) 0.342
(>54 years vs. ≤54 years)
ECOG performance status 3.24 (1.40–7.50) 0.006
(0–1 vs. 2–3)
No. of brain metastases 1.41 (0.74–2.69) 0.299
(1–4 vs. >4)
Max size of brain lesions 1.03 (0.67–1.76) 0.763
(<1 cm vs. >1 cm)
Location of brain lesions 1.62 (0.98–2.73) 0.267
(Brain stem mets vs. Non–brain stem mets)
Other sites of metastatic disease 3.89 (1.58–9.57) 0.002
(No vs. Yes)
EGFR mutation 0.74 (0.39–1.40) 0.351
(Exon 19 vs. Exon 21)
First line systemic treatment 2.43 (1.08–5.48) 0.032
(TKI vs. Chemotherapy)
Time of brain RT 0.77 (0.50–1.19) 0.246
(First line vs. Delayed vs. No RT)
Legend: Each variable was assessed first in univariate analysis, with P value <0.10
regarded as statistically significant. Instead of timing of brain radiotherapy (RT), only
Eastern Cooperative Oncology Group (ECOG) performance status, other distant
metastases and first line systemic treatment were significantly associated with the
overall survival
Table 3 Multivariate analysis of prognostic factors for overall
survival (n = 96)
Variable HR, 95 % CI p value
Other distant metastases 3.53 (1.13–11.08) 0.030
(No vs. Yes)
Legend: The clinical factors that were statistically significant (p < 0.10) in a univariate
analysis were analyzed further in a multivariate analysis with a stepwise selection of
variables. P values <0.05 were regarded as statistically significant in multivariate
analysis. Only other sites of distant metastases were selected by a stepwise
selection of factors in the final models
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Thirty-nine patients were treated initially with brain RT
(13 with stereotactic radiosurgery and 26 with WBRT),
and 23 patients were administered RT when they exhib-
ited brain disease progression (eight with stereotactic ra-
diosurgery and 15 with WBRT). Thirty-four patients did
not receive radiotherapy and remained asymptomatic
until the last follow-up. Univariate analysis revealed that
the timing of brain RT was not significantly related to
OS (p = 0.246, Table 2, Fig. 2). During the follow-up, 54
patients exhibited progressive brain disease after local or
systemic treatment. The 2-year BM PFS was 29.6 %, and
the estimated BM PFS time was 17 months (Fig. 3).
Brain RT as first-line therapy was not significantly asso-
ciated with BM progression-free survival (p = 0.643, HR
0.82, 95 % CI 0.39-1.81, Fig. 4).Fig. 2 Impact of the timing of brain RT on overall survival (p = 0.246,
n = 96): 39 patients were treated initially with brain radiotherapy
(first-line RT), and 23 patients were administered RT when they
exhibited brain disease progression (delayed RT). Thirty-four patients
did not receive radiotherapy and remained asymptomatic until the last
follow-up (no brain RT). Univariate analysis revealed that the timing of
brain RT was not significantly related to OS (p = 0.246)
Fig. 3 Brain metastasis progression free survival since the initiation of
treatment (n = 96): 54 patients exhibited progressive brain disease after
local or systemic treatment. The 2-year brain metastasis progression
free survival (BM PFS) was 29.6 %, and the estimated BM PFS time
was 17 months
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patients received immediate brain RT, eight patients had
delayed brain RT, and eight patients did not receive
brain RT. Univariate analysis showed that the timing of
brain RT was significantly related to OS (P = 0.019,Fig. 4 Impact of the timing of brain RT on BM PFS (p = 0.643, n = 96):
Brain RT as first-line therapy was not significantly associated with BM
PFS (p = 0.643, HR 0.82, 95 % CI 0.39–1.81)Fig. 5). Patients with delayed brain RT had better long-
term survival than the others.
Pattern of treatment failure
Of the 72 (72/96, 75 %) patients who died during follow-
up, 65 (65/96, 68 %) patients died of disease progression,
and the remaining seven died of unknown reasons.
Among the 65 patients, 46 (46/65, 71 %) patients exhib-
ited extra-cranial lesion progression, seven (7/65, 11 %)
patients exhibited intra-cranial lesion progression only,
and 12 (12/65, 18 %) patients exhibited both intra- and
extra-cranial lesion progression. Patients received cross-
over therapies (TKI-Chemotherapy or Chemotherapy-
TKI) when they exhibited systemic disease progression.
Toxicities
The most frequent toxicities observed were nausea,
vomiting, neutropenia and skin rash, and the majority of
toxicities were Grade 2 (G2). Grade 3 vomiting was ob-
served in 24 out of 96 patients (25 %). Grade 3 neutro-
penia occurred in 23 out of 96 patients (24 %). Grade 3
skin rash was observed in 4 out of 96 patients (4.0 %).
No G3-5 neurotoxicity was reported for patients who re-
ceived brain RT. No treatment-related deaths were
recorded.
Discussion
This study retrospectively analyzed a consecutive cohort
of NSCLC patients tested for EGFR mutations. Our re-
sults suggest that among the EGFR-mutated patientsFig. 5 Impact of the timing of brain RT on brain-metastases-only
patients’ overall survival (p = 0.019, n = 35): The timing of brain RT
was significantly related to OS (P = 0.019). Patients with delayed
brain RT had better long-term survival than the others
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significantly related to OS (p = 0.246). Furthermore, sub-
group analysis revealed that brain RT as first-line therapy
was not significantly associated with BM progression-
free survival (p = 0.643). Only the status of other sites of
distant metastases strongly influenced survival after the
commencement of treatment (p = 0.030).
Whole brain radiotherapy is generally the standard
treatment in patients with multiple brain metastases, as
it addresses both macroscopic and microscopic disease.
Whole brain radiotherapy was shown to result in an im-
provement in symptoms in 64–85 % of patients [16–18]
and in a prolonged median survival of 3–6 months [2].
However, WBRT exhibits both short- and long-term tox-
icity. Patients may experience continued fatigue, nausea,
neurocognitive deficits and other general or focal neuro-
logic symptoms during and after the treatment [19, 20].
Soffietti et al. reported the health-related quality-of-life
(HRQOL) results of adjuvant WBRT compared with ob-
servation after either surgery or radiosurgery for a lim-
ited number of brain metastases in patients with stable
solid tumors. Overall, patients in the observation arm re-
ported better HRQOL scores than those who received
WBRT. The differences were clinically relevant during
the early follow-up period (for global health status at
9 months, physical functioning at 8 weeks, cognitive
functioning at 12 months, and fatigue at 8 weeks) [21].
The prevalence of EGFR mutations in BM from
NSCLC patients remains to be determined. Matsumoto
et al. [22] and Gow et al. [11] have reported EGFR muta-
tions in 63 % and 44 % of BM in an Asian study cohort,
respectively. This prevalence is similar to that reported in
primary lung lesions, varying from 30 % to 50 % [23, 24].
Eichler et al. [10] reported that in a cohort of 93 NSCLC
patients with BM, 41 patients (44 %) had mutations in
EGFR. The study demonstrated that a large portion of
NSCLC patients with BMs exhibited EGFR mutations.
Solitary BMs in the absence of other distant metastases
were more common in NSCLC patients with wild-type
EGFR compared with patients with mutated EGFR (31 vs.
7 %, and 35 vs. 12 %, respectively). In the study by Eichler
et al., 18 % of patients with BM were treated initially with
WBRT either alone (53 %) or in combination with craniot-
omy for neurosurgical resection (22 %) or stereotactic ra-
diosurgery (8 %). The median survival from the time of
BM was 11.7 months and was longer for patients with an
EGFR mutation (14.5 vs. 7.6 months, p = 0.09). Multivari-
able analysis suggested that an EGFR mutation (HR: 0.50,
95 % CI: 0.30–0.82), age (HR: 1.03, 95 % CI: 1.00–1.05),
and active extra-cranial disease (HR: 3.30, 95 % CI: 1.70–
6.41) were independently associated with survival. Gow
et al. [11] retrospectively analyzed 63 NSCLC patients
with BM treated by WBRT and found that 46 patients car-
rying EGFR mutations exhibited a median survival of17.3 months compared with 6.6 months for patients with
wild-type EGFR. Additionally, 54 % of patients with EGFR
mutations responded to WBRT compared with only 24 %
in the wild-type group.
Recent studies have reported that despite the issue of
the blood brain barrier, patients with EGFR-mutated BM
exhibit positive responses to TKIs in addition to the
promising response rate to brain RT. Preclinical studies
in mouse models of EGFR-mutant NSCLC BM have
demonstrated the treatment efficacy of gefitinib. [25] A
recent phase II study with 28 patients [26] prospectively
evaluated the efficacy of EGFR TKIs in the treatment of
metastatic brain tumors in NSCLC patients harboring
EGFR mutations. Twenty-three patients (83 %) exhibited
a partial response (PR), and 3 patients (11 %) had stable
disease (SD), representing a disease control rate of 93 %.
The median PFS and OS were 6.6 months (95 % CI,
3.8–9.3 months) and 15.9 months (95 % CI, 7.2–
24.6 months), respectively. There was no difference in
PFS and OS with respect to the EGFR TKI used. After
discontinuation of the treatment, 14 patients (50 %) re-
ceived local therapy (whole-brain radiotherapy or radio-
surgery) for BM during their disease course, with a local
therapy-free interval of 12.6 months (95 % CI, 7.6–
17.6 months). The results implied that EGFR TKI ther-
apy may represent the treatment of choice for BMs in
NSCLC patients harboring an activating EGFR mutation.
Gerber et al. also reported the results of erlotinib versus
radiation therapy for brain metastases in 110 patients
with EGFR-mutant lung adenocarcinoma and found that
there was no significant difference in OS between the
WBRT and erlotinib groups (median, 35 vs. 26 months;
P = 0.62) [27].
In the current study, 23 (23/96, 24 %) patients received
delayed brain RT, because the brain tumors were stable
radiologically with no obvious neurologic symptoms
during initial systemic treatment. Among these 23 pa-
tients, 13 (13/23, 56.5 %) exhibited responses to brain
RT, 6 (6/23, 26.1 %) had stable disease, and 4 (4/23,
17.4 %) developed intra-cranial disease progression. Four
(4/23, 17.4 %) patients died of intra-cranial disease pro-
gression, and 11 (11/23, 47.8 %) patients died of active
distant metastases in other sites. As not all patients re-
ceived brain RT during the disease course and given the
long-term neurotoxicity of WBRT and stereotactic radio-
surgery, a better treatment option may be upfront treat-
ment with EGFR TKIs followed by brain RT at the
appropriate time when neurologic symptoms or signs
develop. There were 35 patients with brain metastases
only in current study, 19 patients received immediate
brain RT, 8 patients had delayed brain RT, and 8 patients
did not receive brain RT. Patients in this subgroup were
more likely to have aggressive treatment. It might be-
cause patients with brain metastasis only were believed
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tiple sites metastases. However, univariate analysis
showed that patients with delayed brain RT had better
long term survival. This result suggested that sequential
treatment (TKI followed by brain RT when brain lesions
progress) might be an optimal choice for these patients.
Since the number of patients in this subgroup remained
limited, further studies should be conducted on this
finding in the future.
Tumors with exon 19 deletions exhibited a higher inci-
dence of CNS involvement compared with tumors bear-
ing the L858R mutation (21 vs. 3 %). Sekine et al. [28]
reported that compared with the wild-type EGFR group
and the exon 21 point mutation group, NSCLC patients
with the exon 19 deletion exhibit a peculiar pattern of
brain metastases, including multiple small metastases
with little brain edema. This metastatic pattern may be
similar to that of miliary brain metastases. In our study,
we included 45 patients with the exon 19 deletion and
51 patients with the exon 21 point mutation. Among the
64 patients with multiple (more than 4) BM lesions, 36
patients exhibited the exon 19 deletion, and 28 patients
had the exon 21 point mutation. There was no signifi-
cant difference between the two EGFR mutation types
with respect to the numbers of BMs (p = 0.934). Consid-
ering all 96 patients, we failed to observe any significant
differences in OS (p = 0.362, HR 0.75, 95 % CI 0.39–1.41)
between the two types of EGFR mutations. The me-
chanism explaining the difference in intra-cranial spread
remains unknown. Epidermal growth factor receptor mu-
tations with the exon 19 deletion have been proposed to
reduce the growth capacity of tumor cells, leading to
smaller-sized BMs. In our study, we did not observe this
phenomenon, possibly because only patients free of CNS
symptoms were enrolled in the analysis.
There are several potential limitations of our current
study. First, patients enrolled in the study received treat-
ment between October 2005 and December 2011; there-
fore, 61 patients were administered chemotherapy as
first-line systemic treatment, and only 35 patients re-
ceived TKIs as first-line treatment. Most of the patients
received crossover regimens (chemotherapy-TKI or TKI-
chemotherapy). Second, although recent studies reported
a discordance rate of 27–28 % for the EGFR mutation sta-
tus between the primary and metastatic sites [29, 30],
pathological and genetic confirmation of BM could not be
performed. Third, there were several other limitations, in-
cluding various chemotherapy regimens and the short
follow-up time. Fourth, there may have been a selection
bias with respect to patients requiring upfront RT and
those patients in whom RT could be delayed. It is possible
that the patients with deferred RT did well because they
had a lower burden of CNS disease and did not require
early WBRT.Conclusions
In conclusion, this study revealed that EGFR TKIs are
very effective for treating NSCLC patients harboring
EGFR mutations and asymptomatic brain metastases.
First-line brain RT did not improve long-term survival
in this cohort of patients. The status of systemic disease
was the strongest prognostic factor for stage IV EGFR-
mutated NSCLC patients. In TKI-naïve patients with an
EGFR mutation and asymptomatic BM, it may be proper
to initiate EGFR TKI therapy and defer upfront brain
RT, particularly in those with active systemic disease.
Prospective studies are needed to validate these clinical
findings.
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